Weighted Average Number of Shares Outstanding, Basic of Protagenic Therapeutics, Inc.\new from 30 Jun 2010 to 31 Dec 2025

Taxonomy & unit
us-gaap: shares
Description
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Summary
Protagenic Therapeutics, Inc.\new quarterly and annual Weighted Average Number of Shares Outstanding, Basic in shares history and change rate from 30 Jun 2010 to 31 Dec 2025.
  • Protagenic Therapeutics, Inc.\new Weighted Average Number of Shares Outstanding, Basic for the quarter ending 31 Dec 2025 was 1,934,878, a 64% decline year-over-year.
  • Protagenic Therapeutics, Inc.\new annual Weighted Average Number of Shares Outstanding, Basic for 2024 was 4,899,953, a 13% increase from 2023.
  • Protagenic Therapeutics, Inc.\new annual Weighted Average Number of Shares Outstanding, Basic for 2023 was 4,344,580, a 0.62% increase from 2022.
  • Protagenic Therapeutics, Inc.\new annual Weighted Average Number of Shares Outstanding, Basic for 2022 was 4,317,875, a 17% increase from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Basic, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Basic, Annual (shares)
Weighted Average Number of Shares Outstanding, Basic, YoY Annual Change (%)

Protagenic Therapeutics, Inc.\new Quarterly Weighted Average Number of Shares Outstanding, Basic (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2025 1,934,878 -3,460,726 -64% 01 Oct 2025 31 Dec 2025 10-Q 09 Mar 2026 2026 Q3
Q3 2025 1,849,389 -3,546,215 -66% 01 Jul 2025 30 Sep 2025 10-Q 26 Nov 2025 2026 Q2
Q2 2025 3,701,226 -1,694,378 -31% 01 Apr 2025 30 Jun 2025 10-QT 10 Sep 2025 2026 Q1
Q1 2025 523,185 +206,381 +65% 01 Jan 2025 31 Mar 2025 10-Q 13 May 2025 2025 Q1
Q4 2024 5,395,604 +1,051,024 +24% 01 Oct 2024 31 Dec 2024 10-Q 09 Mar 2026 2026 Q3
Q3 2024 5,395,604 +1,064,645 +25% 01 Jul 2024 30 Sep 2024 10-Q 26 Nov 2025 2026 Q2
Q2 2024 5,395,604 +1,064,645 +25% 01 Apr 2024 30 Jun 2024 10-QT 10 Sep 2025 2026 Q1
Q1 2024 316,804 -4,001,071 -93% 01 Jan 2024 31 Mar 2024 10-Q 13 May 2025 2025 Q1
Q4 2023 4,344,580 +26,705 +0.62% 01 Oct 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
Q3 2023 4,330,959 +9,644 +0.22% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 4,330,959 +10,786 +0.25% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 4,317,875 +9,462 +0.22% 01 Jan 2023 31 Mar 2023 10-Q 15 May 2024 2024 Q1
Q4 2022 4,317,875 +632,669 +17% 01 Oct 2022 31 Dec 2022 10-K/A 14 May 2024 2023 FY
Q3 2022 4,321,315 -12,200,567 -74% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 4,320,173 -10,167,104 -70% 01 Apr 2022 30 Jun 2022 10-Q 14 Aug 2023 2023 Q2
Q1 2022 4,308,413 -6,212,071 -59% 01 Jan 2022 31 Mar 2022 10-Q 15 May 2023 2023 Q1
Q4 2021 3,685,206 01 Oct 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
Q3 2021 16,521,882 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022 2022 Q3
Q2 2021 14,487,277 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 10,520,484 01 Jan 2021 31 Mar 2021 10-Q 13 May 2022 2022 Q1
Q1 2015 400,000,000 0 0% 01 Jan 2015 31 Mar 2015 10-Q 11 May 2015 2015 Q3
Q4 2014 400,000,000 0 0% 01 Oct 2014 31 Dec 2014 10-Q 06 Feb 2015 2015 Q2
Q3 2014 400,000,000 0 0% 01 Jul 2014 30 Sep 2014 10-Q 13 Nov 2014 2015 Q1
Q2 2014 400,000,000 01 Apr 2014 30 Jun 2014 10-K 14 Oct 2014 2014 FY
Q1 2014 400,000,000 01 Jan 2014 31 Mar 2014 10-Q 11 May 2015 2015 Q3
Q4 2013 400,000,000 01 Oct 2013 31 Dec 2013 10-Q 06 Feb 2015 2015 Q2
Q3 2013 400,000,000 12 Jul 2013 30 Sep 2013 10-Q 13 Nov 2014 2015 Q1
Q3 2011 6,298,662 +1,082,388 +21% 01 Jul 2011 30 Sep 2011 10-Q 14 Nov 2011 2011 Q3
Q2 2011 6,318,601 +1,101,298 +21% 01 Apr 2011 30 Jun 2011 10-Q/A 07 Sep 2011 2011 Q2
Q3 2010 5,216,274 01 Jul 2010 30 Sep 2010 10-Q 14 Nov 2011 2011 Q3
Q2 2010 5,217,303 01 Apr 2010 30 Jun 2010 10-Q/A 07 Sep 2011 2011 Q2

Protagenic Therapeutics, Inc.\new Annual Weighted Average Number of Shares Outstanding, Basic (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 4,899,953 +555,373 +13% 01 Jan 2024 31 Dec 2024 10-K 31 Mar 2025 2024 FY
2023 4,344,580 +26,705 +0.62% 01 Jan 2023 31 Dec 2023 10-K 31 Mar 2025 2024 FY
2022 4,317,875 +632,669 +17% 01 Jan 2022 31 Dec 2022 10-K/A 14 May 2024 2023 FY
2021 3,685,206 01 Jan 2021 31 Dec 2021 10-K 31 Mar 2023 2022 FY
2014 400,000,000 12 Jul 2013 30 Jun 2014 10-K 14 Oct 2014 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.